Oss, The Netherlands, July 21, 2020 —Citryll announced its Board has been strengthened with two
industry veterans with impressive track-records, Businesswire Citryll.

Paul Peter Tak, MD, PhD served as Professor of Medicine and Chair of the Department of Clinical
Immunology and Rheumatology at the Academic Medical Centre/University of Amsterdam (AMC). At
GlaxoSmithKline (GSK) he served as Senior Vice President, Chief Immunology Officer, and Global
Development Leader, and oversaw the creation of a portfolio of new medicines for immune-mediated
inflammatory diseases, cancer and infectious diseases. He has been CEO of Tempero
Pharmaceuticals and Kintai Therapeutics, a Flagship Pioneering company, and served on the Board
of multiple biotech companies.

Eric Meldrum, PhD is currently CSO at ENYO Pharma, a company currently in Phase 2 for Chronic
Hepatitis B and NASH. Eric has 12 years of drug discovery experience at GSK. Until 2005 he was
head of the Asthma and Rhinitis Disease Biology Department responsible for drug development from
early optimization to Phase 2 proof of concept. Since then, Eric has gained 10 years of experience as
CSO in several biotech companies and brings Citryll a depth of experience in translational
approaches to prioritise assets within therapeutic opportunities and the necessary strategic
considerations.

“We warmly welcome Paul Peter and Eric and are incredibly honoured to have them on the Board of
Citryll. Their impressive and complementary track records in drug discovery and development in
pharma, biotech and academia will add significant value to the progression of our NET inhibiting
development candidate CIT-013”, says CEO and executive board member Helmuth van Es.

“The Citryll team is a world leader and pioneer in the NETosis space with a first-in-class, highpotential
therapeutic antibody in development. I am excited to be on its Board and support Citryll to
help advance the lead compound into the clinic and beyond” says Paul Peter Tak.

“This is another great example of top-notch Dutch science and Citryll is a very exciting example of
this. With its labs situated in Oss, the birthplace of one of the world’s most effective PD1 antagonists
and other blockbusters, Citryll and CIT-013 are setup for a similar huge potential” says Eric Meldrum.

Paul Peter Tak will represent investor BOM Brabant Ventures and Eric Meldrum will represent
Brightgene and is chairman. The other non-executive members of the Board are Jos Raats of
ModiQuest, Nora Frey of Seventure Partners and Daniela Couto of BioGeneration Ventures (BGV).
In June 2020 Citryll closed the second round of series A fundraise of in total € 18,5 M/ $21 M with
Seventure and BGV , as new investors and support of existing investors BOM Brabant Ventures,
Brightgene, ModiQuest, Curie capital and RVO.nl.